JP2000500019A5 - - Google Patents

Download PDF

Info

Publication number
JP2000500019A5
JP2000500019A5 JP1997518551A JP51855197A JP2000500019A5 JP 2000500019 A5 JP2000500019 A5 JP 2000500019A5 JP 1997518551 A JP1997518551 A JP 1997518551A JP 51855197 A JP51855197 A JP 51855197A JP 2000500019 A5 JP2000500019 A5 JP 2000500019A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997518551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000500019A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1996/004850 external-priority patent/WO1997018314A1/de
Publication of JP2000500019A publication Critical patent/JP2000500019A/ja
Publication of JP2000500019A5 publication Critical patent/JP2000500019A5/ja
Ceased legal-status Critical Current

Links

JP9518551A 1995-11-16 1996-11-06 ストレプトアビジン融合タンパク質経由でのペプチドの生産方法 Ceased JP2000500019A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19542702 1995-11-16
DE19542702.5 1995-11-16
PCT/EP1996/004850 WO1997018314A1 (de) 1995-11-16 1996-11-06 Verfahren zur herstellung von peptiden über streptavidin-fusionsproteine

Publications (2)

Publication Number Publication Date
JP2000500019A JP2000500019A (ja) 2000-01-11
JP2000500019A5 true JP2000500019A5 (ref) 2004-11-04

Family

ID=7777604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9518551A Ceased JP2000500019A (ja) 1995-11-16 1996-11-06 ストレプトアビジン融合タンパク質経由でのペプチドの生産方法

Country Status (6)

Country Link
US (1) US6136564A (ref)
EP (1) EP0861325A1 (ref)
JP (1) JP2000500019A (ref)
AU (1) AU7566396A (ref)
CA (1) CA2237296C (ref)
WO (1) WO1997018314A1 (ref)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168718A1 (en) * 1997-04-03 2002-11-14 California Institute Of Technology Enzyme-mediated modification of fibrin for tissue engineering
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
WO2000044808A1 (en) 1999-02-01 2000-08-03 Hubbell Jeffrey A Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
EP1190061A1 (en) * 1999-06-07 2002-03-27 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US7291673B2 (en) * 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
EP1465989B1 (en) * 2001-12-18 2008-02-20 Eidgenossisch Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
CA2470419A1 (en) * 2001-12-18 2003-06-26 Eidgenossisch Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US8282912B2 (en) * 2002-03-22 2012-10-09 Kuros Biosurgery, AG Compositions for tissue augmentation
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
CA2592040A1 (en) * 2004-12-22 2006-06-29 Kuros Biosurgery Ag Michael-type addition reaction functionalised peg hydrogels with factor xiiia incorporated biofactors
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
AU2006204461C1 (en) * 2005-01-06 2012-01-12 Baxter Healthcare S.A. Supplemented matrices for the repair of bone fractures
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
ATE543520T1 (de) 2007-04-13 2012-02-15 Kuros Biosurgery Ag Polymergewebeversiegelung
WO2009083544A2 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
JP5501439B2 (ja) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体
SG10201408401RA (en) 2009-09-16 2015-01-29 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
US20130244937A1 (en) 2011-09-02 2013-09-19 Nile Therapeutics, Inc. Chimeric natriuretic peptide compositions and methods of preparation
CN104105711B (zh) 2012-02-10 2018-11-30 弗·哈夫曼-拉罗切有限公司 单链抗体及其他异多聚体
HK1207864A1 (zh) 2012-06-27 2016-02-12 F. Hoffmann-La Roche Ag 用於选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2624470B2 (ja) * 1984-10-02 1997-06-25 バイオジェン インコーポレイテッド ストレプトアビジン様ポリペプチドの製造
GB8518753D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Microbiological products
ATE85345T1 (de) * 1987-03-02 1993-02-15 Forssmann Wolf Georg Neues cadiodilatin-fragment, prozess zu dessen herstellung und dessen anwendung.
GB8723661D0 (en) * 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
ATE253639T1 (de) * 1991-08-19 2003-11-15 Daiichi Suntory Pharma Co Ltd Verfahren zur herstellung von peptiden

Similar Documents

Publication Publication Date Title
JP2000500228A5 (ref)
JP2000500445A5 (ref)
JP2000500440A5 (ref)
JP2000500327A5 (ref)
JP2000500145A5 (ref)
JP2000500155A5 (ref)
JPH11507533A5 (ref)
JP2000500406A5 (ref)
JP2000500361A5 (ref)
JP2000500322A5 (ref)
JP2000500258A5 (ref)
JP2000500342A5 (ref)
JP2000500192A5 (ref)
JPH11506886A5 (ref)
JP2000500226A5 (ref)
JP2000500407A5 (ref)
JP2000500397A5 (ref)
JP2000500166A5 (ref)
JP2000500019A5 (ref)
JP2000500125A5 (ref)
JP2000500346A5 (ref)
JP2000500257A5 (ref)
JPH10510459A5 (ref)
JP2000500429A5 (ref)
JPH11513276A5 (ref)